AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lung Cancer

Shots:

• The P-III FLAURA study involves assessing of Tagrisso (80mg, qd) vs EGFR-TKIs (erlotinib, 50mg, qd /gefitinib, 250mg, qd) in 556 patients with LA/metastatic EGFRm NSCLC across 29 countries
•  In Jul’2017, the P-III FLAURA study met its 1EPs of improvement in PFS and the updated results demonstrated improvement in OS with safety & tolerability profile consistent with the previous studies
• Tagrisso is an irreversible EGFR-TKI targeting both EGFR-sensitizing and EGFR T790M-resistance mutations with clinical activity against CNS metastases and is an approved therapy in 70+ countries for 1L EGFRm advanced NSCLC and in 80+ countries for EGFR T790M mutation-positive advanced NSCLC

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Twitter